Author: admin

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-06-08.

    To ask the Secretary of State for Health, what estimate NHS England has made of the projected savings from the introduction of dose banding of chemotherapy drugs without affecting quality of care.

    George Freeman

    NHS England has advised that the dose banding initiative forms part of its Specialised Commissioning Improving Value programme and can be considered as an expansion of current practice and direction of travel. The dose banding scheme has been primarily designed to deliver improvements in safety and quality of care.

    NHS England advises that the scheme does also have the potential to deliver efficiencies for hospitals and its initial estimate is that this could release up to £5 million of value to the health system.

  • Kate Green – 2016 Parliamentary Question to the Department of Health

    Kate Green – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kate Green on 2016-06-08.

    To ask the Secretary of State for Health, what assessment he has made of the level of access to stroke rehabilitation services in areas that are socio-economically deprived.

    Jane Ellison

    Although the Department has made no assessment of access to stroke rehabilitation in socio-economically deprived areas, the Sentinel Stroke National Audit Programme (SSNAP) undertook an audit in 2015 of the provision and organisation of post-acute stroke care, including rehabilitation services. The audit shows there are variations around the country in the availability of these services to stroke survivors. The Strategic Clinical Networks and the National Clinical Director for Stroke are working with clinical commissioning groups to help address this.

    The SSNAP data can be found at:

    https://www.strokeaudit.org/results/PostAcute/National.aspx

    “

  • Diana Johnson – 2016 Parliamentary Question to the Department of Health

    Diana Johnson – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Diana Johnson on 2016-06-08.

    To ask the Secretary of State for Health, what the budget for NHS Protect was in each of the last eight years.

    George Freeman

    The information requested is in the following table:

    Year

    NHS Protect Budget (£ million)

    NHS Protect staff

    NHS Protect investigators

    2008-09

    13.379

    218

    83

    2009-10

    13.439

    204

    71

    2010-11

    12.121

    217

    68

    2011-12

    11.381

    190

    33

    2012-13

    11.381

    173

    32

    2013-14

    11.381

    178

    32

    2014-15

    11.154

    186

    34

    2015-16

    10.473

    174

    33
  • Stephen Timms – 2016 Parliamentary Question to the Department of Health

    Stephen Timms – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Stephen Timms on 2016-06-08.

    To ask the Secretary of State for Health, what estimate he has made of the cost of rough sleeping to the NHS.

    Jane Ellison

    According to the last Departmental estimate, homeless people – primarily rough sleepers and those living in hostels – cost National Health Service hospitals at least £85 million a year, based on around 40,500 people living in hostels (Healthcare for Single Homeless People (2010).

    Homeless people consume around four times more acute hospital services than the general population. These extra costs arise from the severity of their health conditions and because they are more likely to be admitted as emergency admissions.

    We have made £40 million available through the Homelessness Change/Platform for Life programme to provide tailored hostel accommodation to improve the physical and mental health outcomes of rough sleepers and provide stable, transitional, shared accommodation for young people who are homeless or in insecure housing. We have also encouraged local areas to develop and improve hospital discharge arrangements for people who are homeless through the £10 million Homeless Hospital Discharge Fund, including by more effective multi-agency working.

  • Debbie Abrahams – 2016 Parliamentary Question to the Department of Health

    Debbie Abrahams – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Debbie Abrahams on 2016-06-08.

    To ask the Secretary of State for Health, what assessment he has made of the potential effect on GP services of increasing medical indemnity costs for GPs.

    Alistair Burt

    The Department and NHS England committed in the recently published General Practice Forward View to review the current arrangements for indemnity cover for general practitioners. To take this review forward, a General Practice Indemnity Steering Group has been established by the Department with NHS England to look at the rising cost of indemnity, and to bring forward proposals for discussion by the end of July 2016.

  • Steve McCabe – 2016 Parliamentary Question to the Department of Health

    Steve McCabe – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Steve McCabe on 2016-06-08.

    To ask the Secretary of State for Health, with reference to the Answer of 3 May 2016 to Question 35936, on blood: contamination, when he plans to publish a formal response to the public consultation.

    Jane Ellison

    The consultation on the infected blood payment scheme closed on 15 April 2016. Officials are currently analysing the replies and a formal response will be published as soon as possible.

  • Steve McCabe – 2016 Parliamentary Question to the Department of Health

    Steve McCabe – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Steve McCabe on 2016-06-08.

    To ask the Secretary of State for Health, with reference to the Answer of 15 April 2016 to Question 33132, when he plans to publish details of NHS support funding for community pharmacies under the Pharmacy Access Scheme.

    Alistair Burt

    We expect to publish further details on the Pharmacy Access Scheme at the beginning of July.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-06-08.

    To ask the Secretary of State for Health, what assessment NHS England has made of variation in aseptic services and the delivery of high quality infusional chemotherapy to cancer patients.

    Jane Ellison

    NHS England Specialist Pharmacy Services have to date not undertaken a comprehensive assessment of aseptic capacity to meet the future demands for chemotherapy provision in England. They are currently working closely with colleagues at the Department and NHS Improvement to support a number of regionally based reviews of aseptic capacity and to help trusts develop local and regional Hospital Pharmacy Transformation plans, as recommended by Lord Carter in February 2016.

    The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department and is responsible for regulating unlicensed medicines under a Manufacturer’s ‘Specials’ Licence. The General Pharmaceutical Council (GPhC) and Care Quality Commission (CQC) are responsible for regulating medicine prepared extemporaneously in a register pharmacy or hospital pharmacy respectively under the professional exemption.

    MHRA will collaborate with the NHS, GPhC and CQC though inspections of MHRA licensed aseptic facilities or joint investigations of aseptic facilities in hospitals where there are patient safety concerns.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-06-08.

    To ask the Secretary of State for Health, what steps he is taking to encourage NHS England and the Medicines and Healthcare Products Regulatory Agency to collaborate to ensure aseptic capacity is managed to a commonly high standard, is reimbursed at a sustainable level and supports further investment to meet growing demand in the NHS.

    Jane Ellison

    NHS England Specialist Pharmacy Services have to date not undertaken a comprehensive assessment of aseptic capacity to meet the future demands for chemotherapy provision in England. They are currently working closely with colleagues at the Department and NHS Improvement to support a number of regionally based reviews of aseptic capacity and to help trusts develop local and regional Hospital Pharmacy Transformation plans, as recommended by Lord Carter in February 2016.

    The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department and is responsible for regulating unlicensed medicines under a Manufacturer’s ‘Specials’ Licence. The General Pharmaceutical Council (GPhC) and Care Quality Commission (CQC) are responsible for regulating medicine prepared extemporaneously in a register pharmacy or hospital pharmacy respectively under the professional exemption.

    MHRA will collaborate with the NHS, GPhC and CQC though inspections of MHRA licensed aseptic facilities or joint investigations of aseptic facilities in hospitals where there are patient safety concerns.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-06-08.

    To ask the Secretary of State for Health, what assessment NHS England has made of the capacity in the NHS to meet the demand for aseptic services.

    Jane Ellison

    NHS England Specialist Pharmacy Services have to date not undertaken a comprehensive assessment of aseptic capacity to meet the future demands for chemotherapy provision in England. They are currently working closely with colleagues at the Department and NHS Improvement to support a number of regionally based reviews of aseptic capacity and to help trusts develop local and regional Hospital Pharmacy Transformation plans, as recommended by Lord Carter in February 2016.

    The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department and is responsible for regulating unlicensed medicines under a Manufacturer’s ‘Specials’ Licence. The General Pharmaceutical Council (GPhC) and Care Quality Commission (CQC) are responsible for regulating medicine prepared extemporaneously in a register pharmacy or hospital pharmacy respectively under the professional exemption.

    MHRA will collaborate with the NHS, GPhC and CQC though inspections of MHRA licensed aseptic facilities or joint investigations of aseptic facilities in hospitals where there are patient safety concerns.